0001387131-21-004530.txt : 20210415 0001387131-21-004530.hdr.sgml : 20210415 20210415170352 ACCESSION NUMBER: 0001387131-21-004530 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210415 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210415 DATE AS OF CHANGE: 20210415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 21829219 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_041521.htm CURRENT REPORT
0000887247 false 0000887247 2021-04-15 2021-04-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 15, 2021

 

 

ADAMIS PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

11682 El Camino Real, Suite 300

San Diego, CA

   92130
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

(Former name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADMP  

NASDAQ

Capital Market

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Item 2.02. Results of Operations and Financial Conditions

     

On April 15, 2021, Adamis Pharmaceuticals Corporation (the “Company”) announced certain financial results for the three and twelve months ended December 31, 2020. A copy of the Company’s press release announcing this information and certain other information is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits      

 

Exhibit No.   Description  
     
99.1   Press Release issued April 15, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
     
     
     
Dated: April 15, 2021 By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: Chief Financial Officer

 

 

 

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE

 

Adamis Pharmaceuticals Corporation 8-K

 

 

Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update

 

Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021

 

Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT

 

SAN DIEGO – April 15, 2021 – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced financial results for the year ended December 31, 2020 and provided a business update.

 

“Adamis made significant advancements over the past year and that momentum has carried over into 2021,” stated Dennis J. Carlo, Ph.D., President and Chief Executive Officer of Adamis Pharmaceuticals. “We completed the transition of SYMJEPI to our new commercial partner, US WorldMeds, and we look forward to its continued market penetration and sales growth in 2021. As we announced earlier this week, we recently met with the FDA to discuss the regulatory path forward for ZIMHI in the treatment of opioid overdose, and we intend to resubmit our NDA to the FDA. We also intend to commence our Phase 2/3 clinical trial for Tempol in the second quarter of this year, to evaluate the use of Tempol for the prevention of hospitalization of patients with COVID-19. Earlier this year, we completed an underwritten public offering that raised net proceeds of approximately $48.6 million, which provides the financial flexibility we need to move our programs forward. Adamis has an opportunity to reach several meaningful inflection points that could make 2021 a transformative year for the company.”

 

Product and Pipeline Updates and Other Corporate Developments

 

SYMJEPI (epinephrine) Injection

 

•In October 2020, the SYMJEPI product line, for use in the emergency treatment of acute allergic reactions, completed its transition to a new commercial partner, US WorldMeds.

 

•In January 2021, the SYMJEPI products became available through the Walgreens Prescription Savings Club. The products are being offered at a discounted price of $99.99 per two-pack, which the company believes is the lowest price for an epinephrine device in the U.S.

 

ZIMHI (naloxone) Injection

 

•Adamis submitted responses to the FDA to address the deficiencies identified in a complete response letter (CRL) received in November. Adamis recently met with the FDA to discuss the responses. After the meeting, and based on discussions with the agency, Adamis expects to resubmit the Naloxone NDA within the next 45 days.

 

 

 

 

•Recently, the U.S. Patent and Trademark Office allowed one of Adamis’ patent applications relating to ZIMHI. The claims allowed describe a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection.

 

Tempol

 

•In June 2020, Adamis entered into an exclusive worldwide license for a novel patented compound, Tempol, for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19. Additionally, the license also includes the use of Tempol for reducing radiation dermatitis in patients undergoing treatment for cancer.

 

 •In February 2021, the company announced results from a study in collaboration with Stanford University demonstrated that Tempol inhibited the release of multiple cytokines from activated immune cells of COVID-19 patients, which may be a unique mechanism of action for the agent. In-vivo preclinical data from a hamster virus challenge model has shown an attenuation of the lung pathology and more rapid healing in animals treated with Tempol. This animal model has been used successfully to test vaccines and monoclonal antibodies against COVID-19. These results further support the clinical program of testing Tempol in early COVID.

 

•The company’s IND relating to a protocol for a clinical trial of Tempol in COVID-19 patients received FDA clearance in January 2021. Adamis expects to begin the Phase 2/3 trial during the second quarter of 2021 to examine the effects of Tempol on preventing hospitalization in subjects with COVID-19 infection.

 

Drug Outsourcing Facility

 

•In January, the company announced that it had entered into a non-binding letter of intent with a potential buyer for the sale of substantially all of the assets of its US Compounding, Inc. (USC) registered outsourcing facility subsidiary. Under the terms of the LOI, the buyer would acquire substantially all of the assets of USC, in exchange for a total gross consideration that could range from approximately $10-$20 million, before transaction fees and expenses and other potential post-closing adjustments. Any definitive agreement would be subject to approval by the respective parties, including approval by the board of directors of Adamis, and would likely include customary provisions, including representations and warranties of Adamis and USC, restrictive covenants and indemnification provisions.

 

 

 

 

2020 Financial Results

 

Total revenues for the year ended December 31, 2020 and 2019 were $16.5 million and $22.1 million, respectively. The total revenue decrease was primarily attributable to a decline in sales of products by USC due to restrictions and limitations on outpatient surgery and other medical procedures caused by the COVID-19 pandemic, and related impacts of the pandemic on sales and marketing efforts.

 

Selling, general and administrative expenses for the years ending December 31, 2020 and 2019 were approximately $30.6 million and $25.3 million, respectively. The increase was primarily due to the $7.9 million contingent liability related to the Nephron litigation, offset by the decreases in selling expenses at USC.

 

Research and development expenses were approximately $8.3 million and $10.4 million for the years ended December 31, 2020 and 2019, respectively. The decrease was primarily due to a decrease in development expense for the company’s pipeline candidates.

 

Cash and equivalents at the end of the year was approximately $6.9 million. In January and February 2021, the company received approximately $5.9 million and $48.6 million from the exercise of warrants and an equity financing transaction, respectively.

 

Targeted Potential Milestones

 

•Resubmit the ZIMHI NDA to FDA within the next 45 days
•Start of Phase 2/3 clinical trial of Tempol in COVID-19 patients in the second quarter of 2021
•Progress from non-binding term sheet to executed purchase agreement for the sale of USC outsourcing division in the second half of 2021
•On-going market penetration and increasing sales of SYMJEPI in the U.S. throughout 2021
•Approval and commercial launch of ZIMHI

 

Conference Call

 

Adamis will host a conference call and live webcast today, April 15, 2021 at 2 p.m. PDT (5 p.m. EDT) to discuss its financial and operating results for the fourth quarter 2020 and year ended December 31, 2020, as well as provide an update on business developments and activities.

U.S. Dial-in (Toll Free): 1-877-423-9813

TOLL/International Dial-In: 1-201-689-8573

Conference ID: 13718949

Webcast:  http://public.viavid.com/index.php?id=144486

If you are unable to participate in the live call, a replay will be available shortly after the live event. To listen to the replay please visit the events page of the Adamis investor relations section of the company website at http://ir.adamispharmaceuticals.com/presentations.

 

 

 

About Adamis Pharmaceuticals

 

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company’s subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.

 

Adamis Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or beliefs or that otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning its ability to satisfactorily respond to the matters raised in the FDA’s Complete Response Letter (CRL) relating to the company’s New Drug Application (NDA) for the ZIMHI product, the results of the company’s Type A meeting with the FDA regarding the ZIMHI NDA, and the company’s ability to prepare and resubmit the ZIMHI NDA to the FDA within the time period anticipated by the company, and whether the FDA will accept a resubmitted NDA for review; the company’s beliefs concerning the results of any future studies or clinical trials that the company may conduct relating to Tempol, ZIMHI or its other products or product candidates; the company’s beliefs concerning the anticipated timing of commencement of clinical studies relating to Tempol; the company’s beliefs concerning anticipated commencement and completion dates for clinical trials; the company’s beliefs concerning its ability to commercialize its products and product candidates; the company's beliefs concerning the ability of its product candidates to compete successfully in the market; the company's beliefs concerning the safety and effectiveness of SYMJEPI, ZIMHI or its other products and product candidates; statements about strategies, objectives and our future goals and achievements; future financial results of the company and its subsidiaries; future development and regulatory actions concerning the company’s product candidates; expectations and goals for future growth; guidance regarding future periods; the outcome of the transactions contemplated by the non-binding letter of intent relating to USC; and other statements concerning our future operations and activities. Statements in this press release concerning future events depend on several factors beyond the company's control, including the absence of unexpected developments or delays, market conditions, and the regulatory approval process, and are only predictions and involve known and unknown risks, uncertainties and other factors which may cause Adamis' actual results to be materially different from these forward-looking statements. There can be no assurances concerning the results of the company’s Type A meeting with the FDA regarding the company’s NDA relating to ZIMHI, the timing of any resubmission of the NDA, or that the company will be able to successfully take any actions or develop any additional information that the FDA may require in connection with its review of any resubmitted NDA for ZIMHI. The FDA may require additional studies, or other actions, data or information, relating to the ZIMHI NDA. There can be no assurances that the FDA will regarding the company’s responses to the matters raised in the ZIMHI CRL as satisfactory, concerning the timing or costs of any additional actions that may be required in connection with any resubmission of the NDA, concerning the timing of any resubmission of the ZIMHI NDA, that the FDA will approve any resubmitted NDA relating to our ZIMHI product, that the company will be successful in any formal dispute resolution appeal process with the FDA, or that the product will be able to compete successfully in the market if approved and launched. We may not achieve one or more of the target future milestones described in the press release either within the anticipated time periods or at all. In addition, forward-looking statements concerning our anticipated future activities assume that we have sufficient funding to support such activities and continue our operations and planned activities. As discussed in our filings with the Securities and Exchange Commission, we may require additional funding, and there are no assurances that such funding will be available if required. Failure to timely obtain required funding would adversely affect us and could require us to materially reduce or suspend operations or one or more clinical trials or other product development activities, or delay or prevent our ability to realize the results contemplated by such forward looking statements. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2020, and our subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Except to the extent required by law, any forward-looking statements in this press release speak only as the date of this press release, and Adamis expressly disclaims any obligation to update any forward-looking statements.

 

Contact:

 

Investor Relations at

Adamis Pharmaceuticals Corporation

(858) 997-2400 option 3

IR@adamispharma.com

 

 

 

 EX-101.SCH 3 admp-20210415.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 admp-20210415_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 admp-20210415_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 admp-8k_041521_htm.xml IDEA: XBRL DOCUMENT 0000887247 2021-04-15 2021-04-15 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2021-04-15 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false Common Stock ADMP NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
Apr. 15, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 15, 2021
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_041521.htm admp-20210415.xsd admp-20210415_lab.xml admp-20210415_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_041521.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "admp-8k_041521.htm" ] }, "labelLink": { "local": [ "admp-20210415_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "admp-20210415_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "admp-20210415.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20210415", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_041521.htm", "contextRef": "From2021-04-15to2021-04-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "admp-8k_041521.htm", "contextRef": "From2021-04-15to2021-04-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001387131-21-004530-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-21-004530-xbrl.zip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end